Who are CStone Pharmaceuticals's main competitors?

Named competitors: Junshi Biosciences (1877.HK), Innovent Biologics (1801.HK), Akeso (9926.HK). The cockpit's measured peer set (industry) also includes Viyash Scientific (VIYASH.NS), Sichuan Huiyu Pharmaceutical (688553.SS), Basilea Pharmaceutica (BSLN.SW), Zhejiang Tianyu Pharmaceutical (300702.SZ), Genfleet Therapeutics (Shanghai) (2595.HK), BeBetter Med (688759.SS).

Is CStone Pharmaceuticals expensive compared with its peers?

On ev / sales it trades at 14.8× against a peer median of 3.1×, 2nd most expensive of 19 in its peer set.

How has CStone Pharmaceuticals stock performed?

Over six months to 6 Nov 2026 the shares returned -38.5% against -15.0% for the median peer; over one year -15.2%.

← CockpitCompetitor Analysis › 2616.HK CStone PharmaceuticalsOpen in the cockpit ↗

CStone Pharmaceuticals2616.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese oncology biotech behind sugemalimab (PD-L1 inhibitor), commercialized in China with Pfizer.

≈ A Chinese oncology biotech partnered with a US pharma major for distributionMomentum neutral 42

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$1.07B

US dollars, full cap

Free float

78%

of shares outstanding

$/day

$4.59M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

n/a

WACC 9.1%

Hurdle

n/a

no reverse DCF

Next earnings

146 days

1 Apr 2027

Close · HKDHK$5.34

1D-5.2%

1W+8.2%

1M-7.6%

3M+1.7%

6M-38.5%

YTD+1.4%

1Y-15.2%

ATR %6.9%

52w lowhigh48.7% off high

What CStone Pharmaceuticals does

Chinese oncology biotech behind sugemalimab (PD-L1 inhibitor), commercialized in China with Pfizer.

In one line: A Chinese oncology biotech partnered with a US pharma major for distribution.

Products and services

Sugemalimab (PD-L1 inhibitor)
Oncology pipeline

Customers

Hospitals/oncologists in China
Pfizer (China commercialization partner)

Where it sits in the supply chain

Biotechnology
Immuno-oncology antibodies
Branded biologics

What could go right

Sugemalimab sales ramp via Pfizer distribution

What could go wrong

Competitive PD-1/PD-L1 pricing
Clinical trial risk

Moat: narrow (IP / patents, regulatory licence). Approved PD-L1 antibody with patent protection and a major-pharma distribution partner.

Headquarters: Suzhou, China · Founded: 2015 · Employees: 93

Named competitors

CStone Pharmaceuticals at a glance

Size CStone Pharmaceuticals (2616.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.07B, the 580th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$5.34 on 6 Nov 2026.

Performance Over six months the shares fell 38.5%, against -15.0% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 4th lowest of 20 in its peer set.

Growth Revenue grew 116.7% over the last twelve months (peer median +7.4%); the operating margin is -88.7% (peer median 8.1%).

Valuation It trades at 14.8× enterprise value to sales against a peer median of 3.1× (2nd most expensive of 19).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: CStone Pharmaceuticals against the median of its 20 peers (local-currency closes).

CStone Pharmaceuticals financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	HK$475M	HK$292M	HK$442M	HK$513M	HK$560M
Revenue growth	—	-34%	-14%	-8%	—
Gross profit	HK$218M	HK$7.88M	HK$206M	HK$315M	HK$299M
EBITDA	-HK$372M	-HK$403M	-HK$49.4M	-HK$605M	-HK$997M
Net income	-HK$470M	-HK$474M	-HK$98.9M	-HK$406M	-HK$1.05B
Free cash flow	-HK$315M	-HK$356M	-HK$335M	-HK$711M	-HK$833M
Capital expenditure	HK$0	HK$0	HK$0	HK$71.9M	HK$118M
Total debt	n/a	HK$403M	HK$386M	HK$400M	HK$321M

Quarterly statements and history in the cockpit →

CStone Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. CStone Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CStone Pharmaceuticals is the large dot.

CStone Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (2616.HK vs 1877.HK vs 1801.HK vs 9926.HK)
Company	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g
CStone Pharmaceuticals 2616.HK	$1.07B	-38%	+117%	-89%	14.8×	n/a
Shanghai Junshi Biosciences 1877.HK	$4.08B	-39%	+36%	-14%	9.6×	n/a
Innovent Biologics 1801.HK	$19.2B	-5%	+43%	17%	7.4×	11.7%
Akeso 9926.HK	$10.2B	-38%	+42%	-25%	19.5×	n/a

How CStone Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CStone Pharmaceuticals against its 20 peers (data as of 6 Nov 2026)
Measure	2616.HK	Peer median	Rank in peer set
1-month return	-7.6%	-3.7%	8th lowest of 21
6-month return	-38.5%	-15.0%	4th lowest of 20
Distance from 52-week high	-48.7%	-33.7%	4th lowest of 21
Revenue growth (TTM)	+116.7%	+7.4%	highest of 19
Operating margin	-88.7%	8.1%	2nd lowest of 19
EV / Sales	14.8×	3.1×	2nd most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
CStone Pharmaceuticals 2616.HK	Hong Kong	$1.07B	-38%	+117%	-89%	14.8×	n/a	n/a
Viyash Scientific VIYASH.NS	India	$1.07B	+3%	+96%	13%	3.2×	38.6%	+20.4%
Sichuan Huiyu Pharmaceutical 688553.SS	China	$1.07B	-15%	+8%	7%	4.7×	34.1%	-6.0%
Basilea Pharmaceutica BSLN.SW	Switzerland	$1.07B	+27%	+5%	24%	3.2×	-5.7%	+12.7%
Zhejiang Tianyu Pharmaceutical 300702.SZ	China	$1.08B	-2%	+27%	4%	2.4×	5.0%	+3.5%
Genfleet Therapeutics (Shanghai) 2595.HK	Hong Kong	$1.07B	-47%	-55%	-457%	68.9×	n/a	n/a
BeBetter Med 688759.SS	China	$1.08B	-49%	n/a	n/a	n/a	n/a	n/a
China Resources Boya Bio-pharmaceutical 300294.SZ	China	$1.06B	-18%	-27%	-19%	3.0×	n/a	n/a
Renhe Pharmacy 000650.SZ	China	$1.06B	-10%	-7%	14%	1.0×	-9.4%	-7.0%
Chengdu Easton Biopharmaceuticals 688513.SS	China	$1.09B	-35%	-2%	13%	4.5×	5.5%	+7.7%
Chongqing Taiji Industry (Group) 600129.SS	China	$1.09B	-15%	-4%	2%	1.4×	n/a	n/a
Jiangsu Kanion Pharmaceutical 600557.SS	China	$1.05B	-6%	+8%	7%	1.5×	3.4%	+1.8%
Jiangxi Fushine Pharmaceutical 300497.SZ	China	$1.10B	-29%	+103%	24%	4.3×	8.6%	-4.5%
Ningbo Menovo Pharmaceutical 603538.SS	China	$1.10B	-51%	+19%	9%	4.3×	13.9%	+4.9%
Sunflower Pharmaceutical 002737.SZ	China	$1.04B	-13%	+31%	-7%	1.8×	-6.4%	-7.7%
Bio-Thera Solutions 688177.SS	China	$1.10B	-14%	+24%	-44%	7.6×	n/a	n/a
Blue Jet Healthcare BLUEJET.NS	India	$1.11B	+13%	-28%	28%	11.8×	49.0%	+13.8%
Shandong Lukang Pharmaceutical 600789.SS	China	$1.11B	-13%	-7%	3%	1.6×	3.3%	+6.5%
Towa Pharmaceutical 4553.T	Japan	$1.03B	-16%	+7%	9%	1.2×	1.5%	+12.1%
SAWAI 4887.T	Japan	$1.03B	-22%	+11%	9%	1.3×	n/a	n/a
Symbiotec Pharmalab SYMBIOTEC.NS	India	$1.03B	n/a	n/a	n/a	n/a	n/a	n/a

Questions

Who are CStone Pharmaceuticals's main competitors?: Named competitors: Junshi Biosciences (1877.HK), Innovent Biologics (1801.HK), Akeso (9926.HK). The cockpit's measured peer set (industry) also includes Viyash Scientific (VIYASH.NS), Sichuan Huiyu Pharmaceutical (688553.SS), Basilea Pharmaceutica (BSLN.SW), Zhejiang Tianyu Pharmaceutical (300702.SZ), Genfleet Therapeutics (Shanghai) (2595.HK), BeBetter Med (688759.SS).
Is CStone Pharmaceuticals expensive compared with its peers?: On ev / sales it trades at 14.8× against a peer median of 3.1×, 2nd most expensive of 19 in its peer set.
How has CStone Pharmaceuticals stock performed?: Over six months to 6 Nov 2026 the shares returned -38.5% against -15.0% for the median peer; over one year -15.2%.